Cambrex Corporation
From Wikipedia, the free encyclopedia
| Cambrex Corporation | |
|---|---|
| Type | Public (NYSE: CBM) |
| Founded | 1981 |
| Headquarters | East Rutherford, NJ |
| Key people | James A. Mack, Chairman of the Board, President, CEO Luke M. Beshar, CFO, Executive VP Paulo Russolo, President, Cambrex Profarmaco Business Unit Gary L. Mossman, COO, Executive VP Steven M. Klosk, Executive VP, Administration and COO, Biopharmaceutical Business Unit |
| Industry | Pharmaceutical & Drugs |
| Revenue | ▲$448.55 million USD (FYE 12-31-05) |
| Employees | 800 |
| Website | www.cambrex.com |
Cambrex Corporation is an international pharmaceutical company headquartered in East Rutherford, NJ.
[edit] History
Founded in 1981, Cambrex had grown into more than 2,000 employees before selling off it's biologics to Lonza. Cambrex now has 800 employees. It has sites in Charles City, IA, Tallinn, Estonia, Karlskoga, Sweden, and Milan, Italy.
[edit] Products
Cambrex produces a wide variety of generic and client specified API's and intermediates. Some of their API's include amphetamines (for ADHD medications), anesthetics, cardiovasculars, and vasodilators. Cambrex also has laboratories to manufacture cytotoxic (highly potent) drugs.
